|
|
 |
|
|
Andrew L. Pecora, M.D., FACP
Dr. Pecora is Chairman and Founder of Amorcyte, and a member of the Board of Managers of the Company.
Dr. Pecora currently serves as Chairman and Executive Administrative Director of the cancer center at Hackensack University Medical Center, as well as Managing Partner of the Northern New Jersey Cancer Center (“NNJCC”), a private physicians practice group affiliated with HUMC. Based on his involvement with numerous companies in the development of their products and his management of a large clinical practice and the cancer department of a major health care institution, Dr. Pecora brings a variety of business development and practical business skills to the Company. Dr. Pecora also has significant experience in clinical trials design (Phase I-III), institutional review board practices, conducting clinical trials, and in payor relationships both domestically and on a global basis.
Dr. Pecora is a Professor of Medicine at the University of Medicine and Dentistry of New Jersey. He serves as Chairman of the Board of Directors of Tetralogics, Inc., and is a member of the Board of Directors of Cancer Genetics, Inc. Dr. Pecora is a scientific advisor for numerous state, national and international organizations, and served on the Board of Directors for the American Society for Blood and Marrow Transplantation. Dr. Pecora also currently serves as Chairman, Interim Chief Executive Officer and a member of the Board of Directors of Amorcyte, Inc. In addition, he has served on the Board of Directors for the International Society of Hematotherapy and Graft Engineering and Affiliated Physicians Network, on the Accreditation Committee and as an Inspector for the Foundation for Accreditation of Hematopoietic Cell Therapy.
Dr. Pecora also served on the following:
- the Amgen Stem Cell Factor National Advisory Board;
- the New Jersey State Commission for Core Clinical Advisory Group, Bone Marrow Transplant Subcommittee;
- the Eastern Cooperative Oncology Group Bone Marrow Transplant Review Team;
- the Autologous Blood and Marrow Transplant Registry of North America, Breast Cancer Working Committee;
- the Breast Cancer Task Force for the Bergen County Branch of the American Cancer Society; and
- the Journal of Hematotherapy, Bone Marrow Transplantation and the Journals of Clinical Oncology and BLOOD, as a reviewer.
He was appointed to serve as Chairman of the Transplant Committee of the International Society of Hematotherapy and Graft Engineering. More recently, Dr. Pecora was appointed to a State-of-the-Science Committee convened by the National Cancer Institute and the National Heart, Lung and Blood Institute.
His research interests focus on the study of high-dose therapy and stem cell transplant in the treatment of patients with cancer. He has been actively involved as principal investigator and co-investigator in many national research studies, receiving extensive grant support for his efforts. He has been invited to present his work at numerous scientific meetings and continues to contribute to the published literature.
Dr. Pecora received his medical degree from the University of Medicine and Dentistry of New Jersey, graduating with honors. He went on to complete his medical education in internal medicine at New York Hospital and in hematology and oncology at Memorial Sloan-Kettering Cancer Center, in New York City. He is board certified in internal medicine, hematology, and oncology. He has also received a degree in medical management.
Paul J. Schmitt
Mr. Schmitt has served as Managing Director of Novitas Capital, located in Wayne, Pennsylvania, for more than six years. As Managing Director, he oversees Novitas’ interests in early stage life sciences companies. Previously, Mr. Schmitt was Chairman, President and Chief Executive Officer of Chrysalis International Corporation (NASDAQ: CRLS). Chrysalis was formed in 1996 through the merger of DNX Corporation (NASDAQ: DNXX) and BioClin International. Chrysalis was a leading supplier of pre-clinical and clinical drug development services, including the utilization of transgenic animal science technologies to identify and validate new human genetic targets of disease emerging from worldwide genomic initiatives. Chrysalis’ clients included over 250 biotech and pharmaceutical industry companies in 26 countries. In April 1999, Chrysalis was merged with Phoenix International, Inc. (NASDAQ: PHXI). Prior to forming Chrysalis, Mr. Schmitt joined DNX as the company’s first President and Chief Executive Officer in 1988.
Mr. Schmitt served as a founding trustee of the Biotechnology Council of New Jersey and currently serves on the Board of Managers of the Wistar Institute of the University of Pennsylvania, and the Board of Managers of the Penn State Research Foundation. Mr. Schmitt also serves on the Boards of Directors of seven PA Early Stage Partners Life Sciences portfolio companies, including as Chairman of Azidex Pharmaceuticals. Mr. Schmitt received his B.S. in Finance at Lehigh University (’74), and his MBA from Rutgers University (’79).
John P. Gandolfo
John P. Gandolfo has over 20 years of experience as chief financial officer of rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and medical device areas. Mr. Gandolfo has had direct responsibility over capital raising, financial management, mergers and acquisition transactions and SEC reporting throughout his professional career.
Previously, he was Chief Financial Officer of Power Medical Interventions, Inc. (“PMI”), a publicly held medical device company that manufactures and markets computer assisted endo-mechanical surgical instruments. Since joining PMI in January 2007, Mr. Gandolfo has raised approximately $75 million through a convertible debt offering and IPO of common stock.
From September 2001 through May 2006, he was Chief Financial Officer of Bioject Medical Technologies, Inc., a publicly held supplier of needle free drug delivery systems to the pharmaceutical and biotechnology industries and served on the Company’s Board of Directors from September 2006 through May 2007. While at Bioject, Mr. Gandolfo was responsible for the successful licensing of the Company’s technology to various pharmaceutical companies.
From 1994 through 1999, Mr. Gandolfo was Chief Financial Officer and Chief Operating Officer of Impath, Inc, a publicly held cancer information company that provided diagnostic and prognostic cancer analysis to hospitals and pharmaceutical companies. Impath was sold to Genzyme Genetics in 2004.
From 1987 through 1994, he was Chief Financial Officer of Medical Resources, Inc., a publicly held manager of diagnostic imaging centers throughout the United States.
A graduate of Rutgers University, Mr. Gandolfo is a certified public accountant (inactive status) who began his professional career at Price Waterhouse.
Hans Mueller
Bernard J. Gersh, M.B.Ch.B., D.Phil. F.R.C.P.
Professor of Medicine at Mayo Clinic College of Medicine, Consultant in Cardiovascular Diseases and Internal Medicine and Associate Chair of Academic Affairs and Faculty Development in the Division of Cardiovascular Diseases at Mayo Clinic. His past positions include The W. Proctor Harvey Teaching Professor of Cardiology and Chief of the Division of Cardiology at Georgetown University Medical Center. Dr. Gersh received his MB, ChB, from the University of Cape Town in South Africa. He received his Doctor of Philosophy Degree from Oxford University where he was a Rhodes Scholar. Dr. Gersh is a Fellow of the South African College of Physicians and Royal College of Physicians in the United Kingdom as well as a Fellow of the American College of Cardiology, and the American Heart Association.
Dr. Gersh’s interests include the natural history and therapy of acute and chronic coronary artery disease, clinical electrophysiology, adult congenital heart disease, the cardiomyopathies and the clinical implications of molecular genetics. He has written 585 articles and 117 book chapters. Dr. Gersh is the editor of 11 books and is on the editorial board of 25 journals including Circulation, Journal of the American College of Cardiology (Senior Consulting Editor), Nature Cardiovascular Medicine, and The European Heart Journal (North American Editor). He is a member of the Advisory Board of the Reynolds Foundation, a Past Chairman of the Council of Clinical Cardiology of the American Heart Association, and a former Member of the Board of Trustees of the American College of Cardiology. He has served on the Steering Committees and Data Safety Monitoring Boards of multiple clinical trials, sponsored by the National Lung and Blood Institute and other organizations.
Dr. Gersh’s honors include Teacher of the Year Award from the Division of Cardiovascular Diseases, Mayo Clinic and numerous Visiting Professorships and Invited Lectures both nationally and internationally. He is an Honorary Member of the South African Cardiac Society and The South African Heart Association, and he is an Honorary Fellow of the Sociedad Chilena De Cardiologia Y Cirugia Cardiovascular. He is an Honorary Professor of Medicine at the University of Cape Town, South Africa.
Dr. Gersh was the 2004 recipient of the Distinguished Achievement Award of the AHA Council of Clinical Cardiology and the 2007 recipient of the ACC Distinguished Service Award. Ph.D. (honoris causa) from The University of Coimbra, Portugal in 2005.
Dean J. Kereiakes, M.D
Dean J. Kereiakes, M.D., is Medical Director of The Christ Hospital Heart and Vascular Center, Medical Director of the Carl and Edyth Lindner Center for Research and Education, Chairman, Executive Committee of The Ohio Heart & Vascular Center, and Professor of Clinical Medicine at Ohio State University.
Dr. Kereiakes received his medical degree and was valedictorian of his graduating class at the University of Cincinnati in Ohio. His postgraduate training included internship and residency at the University of California, San Francisco, a senior residency at Massachusetts General Hospital in Boston, and a chief residency at the University of California, San Francisco. He then completed fellowships in adult cardiology at the University of California, San Francisco and in coronary angioplasty at the San Francisco Heart Institute and the Sequoia Hospital. Dr. Kereiakes has been an investigator for most of the interventional technologies introduced in the last two decades and has performed more than 25,000 catheterization laboratory procedures.
In addition to lecturing nationally and internationally, Dr. Kereiakes is very active as a clinical and scientific investigator and has participated in over 800 clinical research protocols. He has published over 600 journal articles, abstracts and book chapters. He serves on the editorial boards of Circulation, The Journal of the American College of Cardiology, Journal of the American College of Cardiology Cardiovascular Interventions, The American Heart Journal, Journal of Invasive Cardiology, The American Journal of Cardiology and The Journal of Interventional Cardiology, as well as being a Section Editor for MedReviews (New Drugs and Devices). He was previously a Section Editor for Circulation.
Dr. Kereiakes is a fellow of the American College of Cardiology. He was a member of the Joint American College of Cardiology/American Heart Association Task Force Committees to write guidelines for both coronary angioplasty and unstable angina. Dr. Kereiakes has been selected as Outstanding Alumnus University of Cincinnati School of Medicine, Who’s Who in America, Who’s Who in Medicine and Healthcare, Who’s Who in Science and Engineering, Best Doctors in America and has received the Cincinnati Business Courier Health Care Hero - Innovator award and the Ohio Valley American Heart Association’s Kaplan Visionary Award for cardiovascular research.
Thomas S. Klitzner, MD, PhD.
Thomas S. Klitzner, MD-PhD is the Jack H. Skirball Professor of Pediatrics and the Vice Chair of Pediatrics at the David Geffen School of Medicine at UCLA. He also serves as the Chief of Pediatric Cardiology at the Mattel Children’s Hospital. He is the immediate past chair of the Section on Cardiology and Cardiac Surgery of the American Academy of Pediatrics and has served as President of the American Heart Association Western States Affiliate and on the executive committee of the California Chapter of the American College of Cardiology. He has published numerous research articles, reviews and book chapters and is a nationally recognized expert in the field of electrophysiology in Pediatrics.
Emerson C. Perin, M.D., Ph.D., FACC.
Dr. Perin is Director, New Interventional Cardiovascular Technology, Texas Heart Institute. He holds academic appointments at Baylor and at The University of Texas Medical School at Houston (UTMSH). Dr. Perin received his medical degree from Federal U. Rio Grande Do Sul in Brazil, and received specialty training at Jackson Memorial Hospital in Miami, Florida and at the Texas Heart Institute. His specialty interests are in cutting-edge interventional cardiology, including transmyocardial laser revascularization, angiogenesis and biosense mapping.
Arshed A. Quyyumi, M.D., FRCP, FACC.
Dr. Quyyumi is Professor of Medicine, Cardiology, at Emory University School of Medicine in Atlanta, Georgia. Prior to his current appointment, Dr. Quyyumi was Senior Investigator and Director, Cardiac Catheterization Lab, at the National Institutes of Health. Dr. Quyyumi received his medical degree from the University of London, England. He completed his residency at Guy’s Hospital, London, and fellowships at National Heart Hospital, London; Massachusetts General Hospital, Boston; and the National Institutes of Health. Dr. Quyyumi’s research focus includes vascular biology, angiogenesis, progenitor cell biology, mechanisms of myocardial ischemia, and the role of genetic and environmental risks on vascular disease. He is the recipient of numerous awards and has published over 160 articles in peer reviewed journals.
Edmund K. Waller , MD, PhD, FACP
Dr. Waller is a Professor of Medicine, hematology/Oncology and Pathology at aEmory University School of Medicine in Atlanta, Georgia. Dr. Waller earned his doctorate at the Rockefeller University in New York and his medical degree at Cornell University. He completed clinical oncology and research (Experimental Pathology with Irv Weissman) fellowships at Stanford University. He currently serves as Director of the Bone Marrow and Stem Cell Transplant Center of Emory University and as the Medical Director for the Stem Cell Processing Laboratory, Hemapheresis Department, and Clinical Trials Office of the Winship Cancer Institute. Dr. Waller’s research focuses on optimizing antitumor immunity in cancer patients. He has funding from the NIH (RO1), LLS, and NMDP. He is developing novel strategies of regulating immune responses by studying the interaction between T cells and dendritic cells. His work includes novel approaches to reduce the ability of donor T-cells to cause graft versus host disease and graft engineering to select donor dendritic cells that enhance graft versus leukemia activities. He has expertise in graft engineering, stem cell selection, and adoptive immunotherapy to treat cancer patients. Dr. Waller is the author of more than 80 peer-reviewed publications and book chapters and 5 patents. He is the recipient of numerous awards and honors including a semi-finalist in the 2002 Entrepreneur Award sponsored by the Walter Coulter Foundation, a Clinical Scholar Award from the Leukemia and Lymphoma Society, a Clinical Investigator Award from the Cancer Research Institute, and a Clinical Scientist Award from the Doris Duke Foundation. He reviews government grants as a member of the Clinical Oncology Study Section of the National Institutes of Health and reviews manuscripts for Blood, Experimental Hematology, Biology of Blood & Marrow Transplantation, Transplantation, New England Journal of Medicine, and Cancer.
James T. Willerson, M.D.
Dr. Willerson is a Edward Randall Professor of Medicine at UT Health Science Center at Houston. Formerly, Dr. Willerson served as the President of The University of Texas Health Science Center at Houston for seven years, where he is also the Alkek-Williams Distinguished Professor and holds the Edward Randall III Chair in Internal Medicine. In October 2004, Dr. Willerson was named President-Elect of the Texas Heart Institute. A renowned cardiologist, he has served as visiting professor and invited lecturer at more than 200 institutions worldwide. Through his most recent research, he and his colleagues at the Texas Heart Institute in Houston and at the Hospital Procardico in Rio de Janeiro, Brazil, in 2001 began bone marrow-derived stem cell transplantation directly into the hearts of patients with severe heart failure resulting in demonstrated evidence of clinical improvement, enhanced blood flow, and improved contractile function.
Joseph C. Wu, M.D., Ph.D., FACC
Dr. Wu is an Assistant Professor in the Department of Medicine (Cardiology) and Department of Radiology at the Stanford School of Medicine. Dr. Wu received his M.D. from the Yale School of Medicine and completed his medicine residency and cardiology fellowship training followed by a PhD (molecular pharmacology) at UCLA. Dr. Wu has received several awards, including the ACC/GE Career Award in Cardiovascular Imaging, Burroughs Wellcome Foundation Career Award in Medical Sciences, Baxter Foundation Faculty Scholar Award, Douglas P. Zipes Distinguished Young Scientist Award, and NIH Director’s New Innovator Award. His lab focuses on research in stem cell biology, gene therapy, genomics, and molecular imaging.
|
|
|
